NCT07319897RecruitingPhase 2/3
68Ga-BCMA PET/CT in Multiple Myeloma
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography/computed tomography (PET/CT) in patients with multiple myeloma and related plasma cell disorders. The study aims to non-invasively visualize and quantify whole-body BCMA expression and to assess its role in the detection of active disease and disease heterogeneity.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 20 Dec 2025
- Start date
- 25 Dec 2025
- Primary completion date
- 30 Dec 2027
- Lead sponsor
- Peking University First Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT07319897
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 300
- From 25 Dec 2025 to the primary completion date, 30 Dec 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- any other condition judged by the investigator to potentially interfere with study participation.
Other
- pregnancy or lactation;
- inability to comprehend study procedures or cooperate with protocol requirements;
Who the study is looking for
- patients with suspected or previously diagnosed multiple myeloma (MM) who were scheduled for bone marrow aspiration or tissue biopsy within two weeks, including those undergoing initial diagnostic evaluation or follow-up/re-evaluation for disease monitoring or relapse;
- patients with confirmed symptomatic MM;
- ability to understand and voluntarily sign written informed consent;
- ability to comply with study procedures;
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tsinghua Changgung Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Beijing An Zhen Hospital of the Capital University of Medical Sciences Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| First Hospital of Jilin University Coordinator of this site? Confirm its status | Jilin City | China | Recruiting |
| The Second Hospital of Hebei Medical University Coordinator of this site? Confirm its status | Shijiazhuang | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.